New York, NY— December 17, 2025, Cartesian Therapeutics, Inc. has chosen Lange Neurology, PC as a trial site for its Phase III study of Descates-08 in patients with generalized myasthenia gravis (MG).

The mission of Cartesian Therapeutics, Inc. is to “leverage new mRNA technologies to extend the potential of cell therapy to patients with autoimmune diseases. “mRNA cell therapy is a new class of therapy that is designed to blend some of the best features of conventional nanoparticle-based mRNA therapy with existing cell therapies.” The phase III study in patients with MG uses CAR-T cell therapy which modifies the patient’s T cells-key components of the immune system-to selectively target and suppress the immune responses that are believed to be responsible for the clinical manifestations of generalized myasthenia gravis.

“We are so excited to be part of this innovative therapy,” said Dr. Lange. “CAR T cell therapy has the potential to bring myasthenia patients into remission for extended periods of time, possibly measured in months or years of remission. The unique science that Cartesian applies to a patient’s T cells obviates the need for chemotherapy and hospitalization, making treatment often as easy as receiving other intravenous therapies. What an exciting time to be participating in clinical trials such as this.”